Reimbursement Review Reports


( Last Updated : April 2, 2015)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Admelog Insulin lispro Cancelled
Advicor Niacin/lovastatin Hypercholesterolemia and mixed dyslipidemia List Complete
Aermony RespiClick fluticasone propionate Asthma Reimburse with clinical criteria and/or conditions Complete
Afinitor Everolimus Pancreatic Neuroendocrine Tumour Reimburse with clinical criteria and/or conditions Complete
Afinitor Everolimus Subependymal giant cell astrocytoma associated with tuberous sclerosis complex Do not list Complete
Afinitor Everolimus Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) Do not list Complete
Afinitor Everolimus Advanced Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Afinitor Everolimus Neuroendocrine tumors (NET) of Gastrointestinal or Lung origin Reimburse with clinical criteria and/or conditions Complete
Aimovig erenumab Migraine Reimburse with clinical criteria and/or conditions Complete
Ajovy fremanezumab migraine Reimburse with clinical criteria and/or conditions Active